We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02993822
Recruitment Status : Completed
First Posted : December 15, 2016
Results First Posted : April 26, 2022
Last Update Posted : April 26, 2022
Sponsor:
Information provided by (Responsible Party):
Nerre Therapeutics Ltd.

Brief Summary:
The purpose of this study is to determine the effectiveness of three doses of orvepitant, taken once a day, in the treatment of chronic refractory cough.

Condition or disease Intervention/treatment Phase
Chronic Refractory Cough Drug: Orvepitant Maleate Drug: Placebo Phase 2

Detailed Description:

A multi-center, double-blind, randomized, parallel group, placebo-controlled dose range study in subjects with chronic refractory cough (CRC).

Doses of orvepitant (10 mg/day, 20 mg/day and 30 mg/day) and placebo will be investigated in four parallel groups.

Each group will compromise of approximately 73 subjects, randomized 1:1:1:1 (approximately 292 subjects in total).

All subjects will enter a three-week screening period to determine eligibility. Eligible subjects will be randomized at the Baseline/Day 1 visit and enter a 12-week double-blind dosing period. During this period there will be four visits at Weeks 2, 4, 8 and 12. There will be a final safety follow-up visit at Week 14.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 315 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo Controlled Study of the Efficacy and Safety of Three Doses of Orvepitant in Subjects With Chronic Refractory Cough
Actual Study Start Date : May 22, 2017
Actual Primary Completion Date : January 14, 2019
Actual Study Completion Date : January 24, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cough

Arm Intervention/treatment
Experimental: Orvepitant 10mg
Orvepitant 10mg tablet, once daily for 12 weeks
Drug: Orvepitant Maleate
Tablet, once daily, oral

Experimental: Orvepitant 20mg
Orvepitant 20mg tablet, once daily for 12 weeks
Drug: Orvepitant Maleate
Tablet, once daily, oral

Experimental: Orvepitant 30mg
Orvepitant 30mg tablet, once daily for 12 weeks
Drug: Orvepitant Maleate
Tablet, once daily, oral

Placebo Comparator: Placebo
Placebo to match tablet, once daily for 12 weeks
Drug: Placebo
Tablet, once daily, oral




Primary Outcome Measures :
  1. Change From Baseline to Week 12 in Awake Objective Cough Frequency [ Time Frame: Baseline to Week 12 ]
    Objective cough frequency measured by ambulatory cough monitoring device


Secondary Outcome Measures :
  1. Change in Awake Objective Cough Frequency at Week 2 Compared to Baseline [ Time Frame: Baseline to Week 2 ]
    Objective cough frequency measured by ambulatory cough monitoring device

  2. Change in Awake Objective Cough Frequency at Week 4 Compared to Baseline [ Time Frame: Week 4 ]
    Objective cough frequency measured by ambulatory cough monitoring device

  3. Change in the Leicester Cough Questionnaire (LCQ) at Week 2 Compared to Baseline [ Time Frame: Baseline to Week 2 ]
    The Leicester Cough Questionnaire (LCQ) is a 19 item questionnaire that assessed cough related quality of life. It has three domains (physical, psychological and social) and subjects were asked to complete it based on their experience in a recall period of 2 weeks. The total score range is 3 to 21 and domain scores each range from 1 to 7; a higher score indicated a better quality of life. Subjects completed the LCQ whilst in the clinic at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  4. Change in the Leicester Cough Questionnaire (LCQ) at Week 4 Compared to Baseline [ Time Frame: Baseline to Week 4 ]
    The Leicester Cough Questionnaire (LCQ) is a 19 item questionnaire that assessed cough related quality of life. It has three domains (physical, psychological and social) and subjects were asked to complete it based on their experience in a recall period of 4 weeks. The total score range is 3 to 21 and domain scores each range from 1 to 7; a higher score indicated a better quality of life. Subjects completed the LCQ whilst in the clinic at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  5. Change in the Leicester Cough Questionnaire (LCQ) at Week 8 Compared to Baseline [ Time Frame: Baseline to Week 8 ]
    The Leicester Cough Questionnaire (LCQ) is a 19 item questionnaire that assessed cough related quality of life. It has three domains (physical, psychological and social) and subjects were asked to complete it based on their experience in a recall period of 8 weeks. The total score range is 3 to 21 and domain scores each range from 1 to 7; a higher score indicated a better quality of life. Subjects completed the LCQ whilst in the clinic at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  6. Change in the Leicester Cough Questionnaire (LCQ) at Week 12 Compared to Baseline [ Time Frame: Baseline to Week 12 ]
    The Leicester Cough Questionnaire (LCQ) is a 19 item questionnaire that assessed cough related quality of life. It has three domains (physical, psychological and social) and subjects were asked to complete it based on their experience in a recall period of 12 weeks. The total score range is 3 to 21 and domain scores each range from 1 to 7; a higher score indicated a better quality of life. Subjects completed the LCQ whilst in the clinic at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  7. Change in the Cough Severity Visual Analogue Scale (VAS) at Week 2 Compared to Baseline - Day-time [ Time Frame: Baseline to Week 2 ]
    The cough VAS is a 100 mm scale on which subjects indicated their severity of cough over the previous 24 hours, both during the day-time and during night time separately. The VAS ranged from "no cough" (0 mm) on the left to "worst cough" (100 mm) on the right. Subjects completed the cough severity VAS at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  8. Change in the Cough Severity Visual Analogue Scale (VAS) at Week 4 Compared to Baseline - Day-time [ Time Frame: Baseline to Week 4 ]
    The cough VAS is a 100 mm scale on which subjects indicated their severity of cough over the previous 24 hours, both during the day-time and during night time separately. The VAS ranged from "no cough" (0 mm) on the left to "worst cough" (100 mm) on the right. Subjects completed the cough severity VAS at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  9. Change in the Cough Severity Visual Analogue Scale (VAS) at Week 8 Compared to Baseline - Day-time [ Time Frame: Baseline to Week 8 ]
    The cough VAS is a 100 mm scale on which subjects indicated their severity of cough over the previous 24 hours, both during the day-time and during night time separately. The VAS ranged from "no cough" (0 mm) on the left to "worst cough" (100 mm) on the right. Subjects completed the cough severity VAS at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  10. Change in the Cough Severity Visual Analogue Scale (VAS) at Week 12 Compared to Baseline - Day-time [ Time Frame: Baseline to Week 12 ]
    The cough VAS is a 100 mm scale on which subjects indicated their severity of cough over the previous 24 hours, both during the day-time and during night time separately. The VAS ranged from "no cough" (0 mm) on the left to "worst cough" (100 mm) on the right. Subjects completed the cough severity VAS at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  11. Change in the Cough Severity Visual Analogue Scale (VAS) at Week 2 Compared to Baseline - Night-time [ Time Frame: Baseline to Week 2 ]
    The cough VAS is a 100 mm scale on which subjects indicated their severity of cough over the previous 24 hours, both during the day-time and during night time separately. The VAS ranged from "no cough" (0 mm) on the left to "worst cough" (100 mm) on the right. Subjects completed the cough severity VAS at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  12. Change in the Cough Severity Visual Analogue Scale (VAS) at Week 4 Compared to Baseline - Night-time [ Time Frame: Baseline to Week 4 ]
    The cough VAS is a 100 mm scale on which subjects indicated their severity of cough over the previous 24 hours, both during the day-time and during night time separately. The VAS ranged from "no cough" (0 mm) on the left to "worst cough" (100 mm) on the right. Subjects completed the cough severity VAS at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  13. Change in the Cough Severity Visual Analogue Scale (VAS) at Week 8 Compared to Baseline - Night-time [ Time Frame: Baseline to Week 8 ]
    The cough VAS is a 100 mm scale on which subjects indicated their severity of cough over the previous 24 hours, both during the day-time and during night time separately. The VAS ranged from "no cough" (0 mm) on the left to "worst cough" (100 mm) on the right. Subjects completed the cough severity VAS at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  14. Change in the Cough Severity Visual Analogue Scale (VAS) at Week 12 Compared to Baseline - Night-time [ Time Frame: Baseline to Week 12 ]
    The cough VAS is a 100 mm scale on which subjects indicated their severity of cough over the previous 24 hours, both during the day-time and during night time separately. The VAS ranged from "no cough" (0 mm) on the left to "worst cough" (100 mm) on the right. Subjects completed the cough severity VAS at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  15. Change in the Urge-to-cough Visual Analogue Scale (VAS) at Week 2 Compared to Baseline [ Time Frame: Baseline to Week 2 ]
    The urge-to-cough VAS was a 100 mm scale on which subjects indicated their urge to cough over the previous 24 hours (day/awake time and night time combined). The VAS ranged from "no urge to cough" (0 mm) on the left to "severe urge to cough" (100 mm) on the right. Subjects completed the urge to cough VAS at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  16. Change in the Urge-to-cough Visual Analogue Scale (VAS) at Week 4 Compared to Baseline [ Time Frame: Baseline to Week 4 ]
    The urge-to-cough VAS was a 100 mm scale on which subjects indicated their urge to cough over the previous 24 hours (day/awake time and night time combined). The VAS ranged from "no urge to cough" (0 mm) on the left to "severe urge to cough" (100 mm) on the right. Subjects completed the urge to cough VAS at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  17. Change in the Urge-to-cough Visual Analogue Scale (VAS) at Week 8 Compared to Baseline [ Time Frame: Baseline to Week 8 ]
    The urge-to-cough VAS was a 100 mm scale on which subjects indicated their urge to cough over the previous 24 hours (day/awake time and night time combined). The VAS ranged from "no urge to cough" (0 mm) on the left to "severe urge to cough" (100 mm) on the right. Subjects completed the urge to cough VAS at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  18. Change in the Urge-to-cough Visual Analogue Scale (VAS) at Week 12 Compared to Baseline [ Time Frame: Baseline to Week 12 ]
    The urge-to-cough VAS was a 100 mm scale on which subjects indicated their urge to cough over the previous 24 hours (day/awake time and night time combined). The VAS ranged from "no urge to cough" (0 mm) on the left to "severe urge to cough" (100 mm) on the right. Subjects completed the urge to cough VAS at baseline/Day 1 (pre dose) and at Weeks 2, 4, 8, and 12.

  19. Global Rating of Change in Cough Frequency at Week 2 [ Time Frame: Baseline to Week 2 ]
    In the Global Rating of Change scale, subjects indicated if there had been a change in their symptoms (cough frequency and, separately, cough severity) since starting the IMP. Subjects responded with "worse", "about the same" or "better". If subjects indicated a change (either "worse" or "better") they then indicated on a 7 point scale the degree of change ranging from 1 (almost the same, hardly any change) to 7 (a very great deal changed). Subjects documented their Global Rating of Change in cough frequency and cough severity at Weeks 2, 4, 8, and 12.

  20. Global Rating of Change in Cough Frequency at Week 4 [ Time Frame: Baseline to Week 4 ]
    In the Global Rating of Change scale, subjects indicated if there had been a change in their symptoms (cough frequency and, separately, cough severity) since starting the IMP. Subjects responded with "worse", "about the same" or "better". If subjects indicated a change (either "worse" or "better") they then indicated on a 7 point scale the degree of change ranging from 1 (almost the same, hardly any change) to 7 (a very great deal changed). Subjects documented their Global Rating of Change in cough frequency and cough severity at Weeks 2, 4, 8, and 12.

  21. Global Rating of Change in Cough Frequency at Week 8 [ Time Frame: Baseline to Week 8 ]
    In the Global Rating of Change scale, subjects indicated if there had been a change in their symptoms (cough frequency and, separately, cough severity) since starting the IMP. Subjects responded with "worse", "about the same" or "better". If subjects indicated a change (either "worse" or "better") they then indicated on a 7 point scale the degree of change ranging from 1 (almost the same, hardly any change) to 7 (a very great deal changed). Subjects documented their Global Rating of Change in cough frequency and cough severity at Weeks 2, 4, 8, and 12.

  22. Global Rating of Change in Cough Frequency at Week 12 [ Time Frame: Baseline to Week 12 ]
    In the Global Rating of Change scale, subjects indicated if there had been a change in their symptoms (cough frequency and, separately, cough severity) since starting the IMP. Subjects responded with "worse", "about the same" or "better". If subjects indicated a change (either "worse" or "better") they then indicated on a 7 point scale the degree of change ranging from 1 (almost the same, hardly any change) to 7 (a very great deal changed). Subjects documented their Global Rating of Change in cough frequency and cough severity at Weeks 2, 4, 8, and 12.

  23. Global Rating of Change in Cough Severity at Week 2 [ Time Frame: Baseline to Week 2 ]
    In the Global Rating of Change scale, subjects indicated if there had been a change in their symptoms (cough frequency and, separately, cough severity) since starting the IMP. Subjects responded with "worse", "about the same" or "better". If subjects indicated a change (either "worse" or "better") they then indicated on a 7 point scale the degree of change ranging from 1 (almost the same, hardly any change) to 7 (a very great deal changed). Subjects documented their Global Rating of Change in cough frequency and cough severity at Weeks 2, 4, 8, and 12.

  24. Global Rating of Change in Cough Severity at Week 4 [ Time Frame: Baseline to Week 4 ]
    In the Global Rating of Change scale, subjects indicated if there had been a change in their symptoms (cough frequency and, separately, cough severity) since starting the IMP. Subjects responded with "worse", "about the same" or "better". If subjects indicated a change (either "worse" or "better") they then indicated on a 7 point scale the degree of change ranging from 1 (almost the same, hardly any change) to 7 (a very great deal changed). Subjects documented their Global Rating of Change in cough frequency and cough severity at Weeks 2, 4, 8, and 12.

  25. Global Rating of Change in Cough Severity at Week 8 [ Time Frame: Baseline to Week 8 ]
    In the Global Rating of Change scale, subjects indicated if there had been a change in their symptoms (cough frequency and, separately, cough severity) since starting the IMP. Subjects responded with "worse", "about the same" or "better". If subjects indicated a change (either "worse" or "better") they then indicated on a 7 point scale the degree of change ranging from 1 (almost the same, hardly any change) to 7 (a very great deal changed). Subjects documented their Global Rating of Change in cough frequency and cough severity at Weeks 2, 4, 8, and 12.

  26. Global Rating of Change in Cough Severity at Week 12 [ Time Frame: Baseline to Week 12 ]
    In the Global Rating of Change scale, subjects indicated if there had been a change in their symptoms (cough frequency and, separately, cough severity) since starting the IMP. Subjects responded with "worse", "about the same" or "better". If subjects indicated a change (either "worse" or "better") they then indicated on a 7 point scale the degree of change ranging from 1 (almost the same, hardly any change) to 7 (a very great deal changed). Subjects documented their Global Rating of Change in cough frequency and cough severity at Weeks 2, 4, 8, and 12.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Male and female subjects ≥18 years of age.
  • Diagnosis of CRC or unexplained cough for at least 1 year (see ACCP/BTS guidelines attached).
  • An awake average cough frequency of ≥10 coughs/ hour, as assessed using an ACM during the screening period.

Key Exclusion Criteria:

  • Subjects with respiratory tract infection (<4 weeks prior to study start)
  • Current smokers or ex-smokers with <6 months' abstinence or cumulative history of >10 pack years
  • Treatment with Angiotensin Converting Enzyme (ACE) inhibitors within 3 months of screening
  • FEV1 <80% predicted, measured at screening using spirometry
  • History of cystic fibrosis, idiopathic pulmonary fibrosis, clinically significant bronchiectasis, moderate to severe asthma, chronic obstructive pulmonary disease (COPD)
  • Any clinically significant abnormal laboratory test result(s)
  • Inability to comply with the use of prohibited and allowed medications as described in the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02993822


Locations
Show Show 66 study locations
Sponsors and Collaborators
Nerre Therapeutics Ltd.
  Study Documents (Full-Text)

Documents provided by Nerre Therapeutics Ltd.:
Study Protocol  [PDF] February 21, 2018
Statistical Analysis Plan  [PDF] May 8, 2018

Layout table for additonal information
Responsible Party: Nerre Therapeutics Ltd.
ClinicalTrials.gov Identifier: NCT02993822    
Other Study ID Numbers: VOLCANO-2
First Posted: December 15, 2016    Key Record Dates
Results First Posted: April 26, 2022
Last Update Posted: April 26, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cough
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Maleic acid
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action